Friday, September 4, 2026

Clinical Trial News: July-August 2026

FDA Drug Approvals

  • 07-Jul-2026: Trutakna (atacicept-vmjy)
    FDA approved Trutakna to reduce proteinuria in adults with primary IgA nephropathy. FDA

  • 13-Jul-2026: Leqembi (lecanemab)
    FDA approved the first at-home starting dose option for Alzheimer's disease treatment, potentially reducing the burden of initiating therapy in an infusion setting. FDA

  • 16-Jul-2026: Lipfendra (enlicitide)
    Approved as the first oral PCSK9 inhibitor for lowering LDL cholesterol. FDA

  • 19-Aug-2026: Pasatru (garetosmab-grts)
    Approved as the second treatment for fibrodysplasia ossificans progressiva, a rare disorder involving abnormal bone formation. FDA

  • 25-Aug-2026: Imaavy (nipocalimab-aahu)
    Approved as the first drug for warm autoimmune hemolytic anemia. FDA

  • 26-Aug-2026: Rasonque (daraxonrasib)
    Approved as a first-in-class RAS inhibitor for metastatic pancreatic cancer. FDA

  • 27-Aug-2026: Lisraya (brepocitinib)
    Approved as the first oral drug specifically indicated for adult dermatomyositis. FDA

  • 28-Aug-2026: Mimrylo (rusfertide)
    Approved as the first drug of its kind for adults with polycythemia vera. FDA

  • 31-Aug-2026: Besremi (ropeginterferon alfa-2b-njft)
    FDA approved Besremi for essential thrombocythemia. FDA

  • 06-Aug-2026: Tudriqev (vusolimogene oderparepvec-wtpg)
    Accelerated approval granted for this engineered oncolytic viral immunotherapy in combination with nivolumab for treatment-resistant advanced melanoma. FDA

FDA takeaway: July and August featured several first-in-class or highly differentiated therapies across oncology, rare disease, immunology, cardiovascular disease and CNS. FDA 2026 Novel Drug Approvals

Regulatory Updates

United States: FDA

  • 16-Jul-2026: Oncology trial eligibility guidance
    FDA finalized recommendations addressing laboratory values, performance status, and washout periods in cancer trials. The goal is to reduce unnecessarily restrictive eligibility criteria and improve patient access.

  • 18-Aug-2026: Generative AI regulation
    FDA requested public feedback on its regulatory approach for generative-AI-enabled medical devices. FDA

  • 25-Aug-2026: Digital health
    FDA authorized the first wearable device capable of continuously monitoring both glucose and ketones. FDA

European Union: EMA

  • 23-Jul-2026: CHMP recommendations
    EMA's CHMP recommended 12 medicines for approval, including treatments for oncology, cardiovascular disease, dermatology and rare disease. EMA

  • Jul-Aug 2026: CTIS modernization
    EMA continued work on simplifying Clinical Trial Information System processes and improving safety reporting. EMA

United Kingdom: MHRA

  • 17-Aug-2026: Phase 1 14-Day Pilot
    MHRA published its pilot program to reduce the first regulatory assessment cycle for qualifying Phase 1 healthy-volunteer trials toward 14 calendar days. MHRA

Canada: Health Canada

  • 29-Jul-2026: Clinical trial transparency
    Updated guidance strengthened requirements and expectations around registration and public disclosure of clinical-trial information. Health Canada

  • 15-Jul-2026: Regulatory reliance
    Health Canada introduced a framework allowing greater use of trusted foreign regulatory assessments to reduce duplication and speed access. Health Canada

Australia: TGA

  • 03-Aug-2026: TAVNEOS review
    TGA began reviewing avacopan after concerns were raised about the integrity and reliability of supporting clinical-trial data. TGA

China: NMPA

  • 20-Aug-2026: AI + drug regulation
    NMPA released implementation guidance covering the use of AI in drug review, inspection, testing and surveillance. NMPA

Key Trial Results

  • 23-Jul-2026: Povorcitinib in hidradenitis suppurativa
    The Phase 3 STOP-HS1 and STOP-HS2 trials were published in Nature Medicine, supporting continued development of povorcitinib for moderate-to-severe hidradenitis suppurativa. Nature Medicine

  • 17-Aug-2026: Enhertu in HER2-mutant NSCLC
    DESTINY-Lung04 met its primary endpoint, showing statistically significant and clinically meaningful improvement in progression-free survival in the first-line setting. AstraZeneca

  • 19-Aug-2026: Intismeran autogene
    Merck and Moderna reported positive Phase 3 INTerpath-001 results. The personalized mRNA cancer vaccine plus Keytruda improved recurrence-free and distant metastasis-free survival in resected melanoma. Merck

  • 29-Aug-2026: TNX-103 follow-up data
    Additional Phase 3 LEVEL results showed biologic activity in a lower-function subgroup, including improvement in six-minute walk distance and reductions in NT-proBNP. Tenax

Why it matters: Personalized cancer vaccines and targeted therapies are moving closer to routine clinical development, while obesity and oncology continue to generate some of the largest potential commercial opportunities.

Clinical Trial Setbacks

  • 09-Jul-2026: Wainua
    AstraZeneca and Ionis reported that the Phase 3 CARDIO-TTRansform trial failed to meet its primary composite cardiovascular endpoint in ATTR-CM. AstraZeneca

  • 10-Aug-2026: TNX-103
    Tenax reported that the Phase 3 LEVEL study did not meet its primary endpoint of improving six-minute walk distance. Tenax

  • Jul-2026: EPCORE DLBCL-1
    AbbVie and Genmab clarified that overall survival was the sole U.S. primary endpoint and that it was not met. AbbVie

The lesson: Strong biomarkers, biological rationale and encouraging subgroups do not guarantee a successful registrational endpoint.

Technological Breakthroughs

  • 19-Aug-2026: Robotic blood draws
    FDA authorized Aletta, the first standalone robotic blood-draw device. FDA

  • 25-Aug-2026: Continuous monitoring
    FDA authorized a wearable capable of continuously monitoring glucose and ketones. FDA

  • Jul-Aug 2026: Digital endpoints
    FDA continued work on digitally derived measures from wearables, sensors and other technologies.

  • 19-Aug-2026: Personalized manufacturing
    Positive Phase 3 cancer-vaccine data highlights the potential of individualized treatment manufacturing, but also adds significant operational and supply-chain complexity.

AI Latest News

  • 18-Aug-2026: FDA and GenAI
    FDA launched a public discussion on the regulation of generative-AI-enabled medical devices. FDA

  • 10-Aug-2026: Novo Nordisk + AWS
    Novo Nordisk selected AWS as a strategic AI and cloud partner to accelerate drug discovery and modernize R&D. A new London co-innovation hub will combine AI specialists with Novo Nordisk research teams. Novo Nordisk

  • Aug-2026: AI and clinical development
    Pharmaceutical companies continued expanding AI into study design, document generation, data analysis and regulatory workflows.

  • 2026: Real-world AI evidence
    Emerging research increasingly shows that model accuracy alone is not enough. Adoption depends on whether AI actually improves workflow, decisions and outcomes.

The big AI lesson: The winning applications won't necessarily be the ones generating the most content. They'll be the ones that remove unnecessary work or improve a decision.

M&A Deals

  • 06-Jul-2026: Vertex acquires Crinetics
    Approximately $10 billion. Adds Palsonify and a late-stage endocrine pipeline. Vertex

  • 06-Jul-2026: Novartis acquires Myricx Bio
    Up to $1.5 billion, including $1.1 billion upfront. Focused on next-generation ADC payload technology. Novartis

  • 16-Jul-2026: Lilly acquires AtaiBeckley
    Approximately $2.8 billion upfront plus up to $1 billion in milestones, expanding Lilly's neuroscience pipeline. Lilly

  • 03-Aug-2026: Curium and Lantheus
    Transaction valued at up to $8 billion, combining radiopharmaceutical diagnostics and therapeutics. Curium

  • 31-Aug-2026: Lilly acquires Merida Biosciences
    Up to $2.875 billion, expanding Lilly's autoimmune and allergy pipeline. Reuters

M&A takeaway: Big Pharma continues buying differentiated platforms, late-stage assets and technologies that can fill future pipeline gaps.

Market Insights

  • Jul-Aug 2026: Biotech capital markets strengthen
    IPO activity continued to improve compared with 2025, giving clinical-stage companies additional access to capital.

  • Jul-Aug 2026: M&A remains strong
    Oncology, immunology, CNS, radiopharmaceuticals and rare disease remained major areas for deal activity.

  • Aug-2026: Investors remain selective
    Strong clinical evidence and differentiated platforms continue to attract capital, while earlier-stage companies face greater scrutiny.

  • 2026: Patent-cliff pressure continues
    Large pharmaceutical companies are increasingly using M&A and licensing to replace future revenue threatened by loss of exclusivity.

Pipeline: Q4 2026 & 2027

  • 27-Nov-2026: BBP-418, BridgeBio
    FDA PDUFA date for limb-girdle muscular dystrophy R9.

  • 28-Nov-2026: D-PLEX100, PolyPid
    FDA PDUFA date for prevention of surgical-site infections.

  • 12-Dec-2026: Imsidolimab, Vanda
    FDA PDUFA date for generalized pustular psoriasis.

  • Q1 2027: Retatrutide, Eli Lilly
    Planned BLA submission for obesity following Phase 3 development.

  • 14-Apr-2027: Ozekibart, Inhibrx
    FDA PDUFA date for conventional chondrosarcoma.

  • 28-Apr-2027: Varegacestat, Immunome
    FDA PDUFA date for desmoid tumors.

  • 08-May-2027: Encaleret, BridgeBio
    FDA PDUFA date for autosomal dominant hypocalcemia.

  • Q1 2027: OPERA-01, Olema
    Expected Phase 3 topline results in breast cancer.

  • 2H 2027: Bel-sar, Aura Biosciences
    Expected Phase 3 topline results in ocular oncology.

Summary

DateCategoryCompany / DrugKey Development
07-Jul-2026FDA ApprovalTrutaknaIgA nephropathy
16-Jul-2026FDA ApprovalLipfendraFirst oral PCSK9 inhibitor
17-Aug-2026RegulatoryMHRAPhase 1 14-day pilot
19-Aug-2026Trial ResultIntismeran autogenePositive Phase 3 melanoma results
19-Aug-2026TechnologyAlettaFirst robotic blood-draw device
25-Aug-2026TechnologyGlucose/ketone wearableFirst continuous dual monitoring device
26-Aug-2026FDA ApprovalRasonqueFirst-in-class targeted pancreatic cancer therapy
28-Aug-2026FDA ApprovalMimryloFirst drug of its kind for polycythemia vera
03-Aug-2026M&ACurium / LantheusUp to $8B
31-Aug-2026M&ALilly / MeridaUp to $2.875B
Q4 2026PipelineMultiple assetsSeveral major PDUFA dates
2027PipelineRetatrutide + othersMajor obesity, oncology and rare-disease catalysts

The Big Picture

  • Obesity: The next generation is moving beyond traditional GLP-1 therapy toward multi-agonists and oral treatments.

  • Oncology: Personalized vaccines, ADCs, targeted therapies and immunotherapies continue driving innovation.

  • Regulation: FDA, EMA, MHRA and other agencies are working to reduce unnecessary trial friction while increasing evidence expectations.

  • AI: The focus is shifting from AI that generates content to AI that improves clinical and operational decisions.

  • M&A: Big Pharma continues using acquisitions and licensing to rebuild pipelines before upcoming patent losses.

  • 2027: Expect heavy activity across obesity, oncology, CNS and rare disease.

Quick Links

- No comments:
Subscribe to: Posts (Atom)